Tristel

At APIC 2026 in Nashville, Tristel — together with distributor Parker Laboratories — presented its FDA-cleared chlorine dioxide foam product Tristel ULT for high-level disinfection of ultrasound probes, highlighting operational benefits such as faster treatment cycles and lower maintenance costs. The company also introduced Tristel ORL, an on-site foam for high-level disinfection of ENT instruments with a two-minute contact time; Tristel is seeking FDA approval for ORL, which is already registered in Canada. In addition, Tristel launched Tristel 3T Pro, the first paid tier of its digital compliance platform offering customization, reporting, and audit-preparation features. » More on de.investing.com

Tristel reports revenue growth of 14% for July to December (approximately £25.7m calculated), a stable gross margin of 81% and an EBITDA margin of 28%, thus above the target of at least 25%. The US business shows continued progress and revenue growth was in line with internal forecasts. The figures make the stock an increasingly notable small-cap story. » More on de.investing.com

Tristel reports an 11% increase in revenue for the 24/25 financial year to £46.5m and a gross margin of 81%. Adjusted EBITDA rose 20% to £13m, with an adjusted EBITDA margin of 28%, above the 25% target. CEO Matt Sassone and new CFO Anna Wasyl presented the results at the investor conference, signaling growth potential and a rising dividend profile. » More on de.investing.com